DNTH Stock Slips 20%: Investors Eye Long‑Acting Monoclonal Antibody Future
DNTH’s share price dips after a 20% plunge, but its long‑acting monoclonal antibody platform could still offer upside amid autoimmunity market demand.
- DIANTHUS THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read